ArticleScientific reports2026
A pilot human-based study of
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Imaging of MASLD: clinical standards and novel methods.Diabetologia · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
To explore the potential value of 68Ga-FAPI-04 PET/CT in staging liver fibrosis of patients with chronic liver diseases, and to preliminarily compare its diagnostic performance with Fibroscan and the fibrosis-4 (FIB-4) index. The single-center prospective study enrolled participants with chronic liver diseases who had undergone liver biopsy. 68Ga-FAPI-04 PET/CT grading is conducted through a scoring system: TBRliver−to−blood greater than 2 as F4, TBRliver−to−blood between 1 and 2 as F2/3, and TBRliver−to−blood less than 1 as F0/1. The diagnostic performance of 68Ga-FAPI-04 PET/CT was preliminarily compared with Fibroscan and FIB-4 using accuracy and weighted Kappa values. A total of 14 participants (8 men, 6 women) were enrolled. According to the METAVIR scoring system, 6 participants (43%) had F0/1 fibrosis, 4 (28%) had F2, and 4 (28%) had F4. The TBRliver−to−blood in the F0/1 group (0.83 ± 0.07) was significantly lower than that in the F4 group (2.12 ± 0.78) (P = 0.010). Using a TBRliver−to−blood > 1 for 68Ga-FAPI-04 to diagnose F ≥ 2 fibrosis yielded a sensitivity of 87.5%, specificity of 83.3%, and PPV of 87.5%. Both FIB-4 and Fibroscan correctly classified 10/14 (71.4%) participants (weighted Kappa values: 0.696 and 0.598, respectively). 68Ga-FAPI-04 PET/CT successfully differentiated 12/14 (85.7%) participants (weighted Kappa = 0.841). The results of this preliminary study suggest that 68Ga-FAPI-04 PET/CT may be an effective non-invasive method for assessing liver fibrosis and could potentially outperform FIB-4 and Fibroscan. Further clinical trials are warranted for validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.